Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: News Direct
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.23
-4.54 (-1.75%)
AAPL  324.83
+7.98 (2.52%)
AMD  454.92
-15.80 (-3.36%)
BAC  61.95
+0.02 (0.02%)
GOOG  331.67
-3.74 (-1.12%)
META  582.44
+10.10 (1.76%)
MSFT  500.95
-6.34 (-1.25%)
NVDA  217.84
-2.94 (-1.33%)
ORCL  140.85
-8.27 (-5.55%)
TSLA  355.12
-12.82 (-3.49%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.